300 related articles for article (PubMed ID: 32797372)
1. Satralizumab: First Approval.
Heo YA
Drugs; 2020 Sep; 80(14):1477-1482. PubMed ID: 32797372
[TBL] [Abstract][Full Text] [Related]
2. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
3. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
[TBL] [Abstract][Full Text] [Related]
5. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
Duchow A; Bellmann-Strobl J
Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
[TBL] [Abstract][Full Text] [Related]
6. Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders.
Paton DM
Drugs Today (Barc); 2021 Mar; 57(3):209-218. PubMed ID: 33729218
[TBL] [Abstract][Full Text] [Related]
7. [Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder].
Prakhova LN; Krasnov VS; Kasatkin DS; Korobko DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):68-72. PubMed ID: 35912559
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
Duchow A; Paul F; Bellmann-Strobl J
Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
[TBL] [Abstract][Full Text] [Related]
9. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
Valencia-Sanchez C; Wingerchuk DM
BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
[TBL] [Abstract][Full Text] [Related]
10. Inebilizumab: First Approval.
Frampton JE
Drugs; 2020 Aug; 80(12):1259-1264. PubMed ID: 32729016
[TBL] [Abstract][Full Text] [Related]
11. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report.
Li X; Wu W; Zeng Y; Wu W; Hou C; Zhu H; Liao Y; Tian Y; Chen Z; Peng B; Chen WX
Front Immunol; 2023; 14():1257955. PubMed ID: 37915570
[TBL] [Abstract][Full Text] [Related]
12. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
Wallach AI; Tremblay M; Kister I
Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
[TBL] [Abstract][Full Text] [Related]
13. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders.
Gao Y; Zhang B; Yang J
Ann Pharmacother; 2021 Sep; 55(9):1167-1171. PubMed ID: 33246373
[TBL] [Abstract][Full Text] [Related]
14. Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient.
Pestchanker C; Diaconchuk M; Lopez P; Montaño MR; Romero W; Zalazar G; Carnero Contentti E
Mult Scler; 2023 Jan; 29(1):150-153. PubMed ID: 36437566
[TBL] [Abstract][Full Text] [Related]
15. Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.
Rosso M; Saxena S; Chitnis T
Expert Rev Neurother; 2020 May; 20(5):509-516. PubMed ID: 32306778
[No Abstract] [Full Text] [Related]
16. SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
Bennett JL; Fujihara K; Kim HJ; Marignier R; O'Connor KC; Sergott RC; Traboulsee A; Wiendl H; Wuerfel J; Zamvil SS; Anania VG; Buffels R; Künzel T; Lekkerkerker AN; Lennon-Chrimes S; Pittock SJ
Front Neurol; 2023; 14():1114667. PubMed ID: 36873431
[TBL] [Abstract][Full Text] [Related]
17. Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment.
Uzawa A; Mori M; Iwai Y; Masuda H; Kuwabara S
Intern Med; 2022 Sep; 61(18):2785-2787. PubMed ID: 35135926
[TBL] [Abstract][Full Text] [Related]
18. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K
Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202
[TBL] [Abstract][Full Text] [Related]
19. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Nie T; Blair HA
CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
[TBL] [Abstract][Full Text] [Related]
20. Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor.
Meher BR; Mohanty RR; Dash A
Cureus; 2024 Feb; 16(2):e55100. PubMed ID: 38558672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
